SBIR Phase I:Controlled Topical Delivery of Nitric Oxide for Wound Healing and Efficacy Assessment by Optical Monitoring

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1013789
Agency Tracking Number: 1013789
Amount: $150,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2010
Solicitation Year: 2010
Solicitation Topic Code: BC
Solicitation Number: NSF 09-609
Small Business Information
Zeomedix
26 Ashlawn Circle, Malvern, PA, 19355
DUNS: 832603067
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 John Aybar
 DPhil
 (610) 517-7818
 aybarc@gmail.com
Business Contact
 John Aybar
Title: DPhil
Phone: (610) 517-7818
Email: aybarc@gmail.com
Research Institution
N/A
Abstract
This Small Business Innovation Research (SBIR) Phase I project is about developing an effective product for chronic wounds of the lower extremity; diabetic foot ulcers and venous leg ulcers. The basic technology is zeolites that contain nitric oxide, an agent that has proven effective in treating chronic wounds. However, since NO is a gas, NO delivery to the desired area is difficult. New products designed to maintain optimal levels of NO during the various phases of wound healing would be important solutions for enhanced healing of chronic wound. This project has two aims: a) prove efficacy of zeolites containing NO in improving healing in chronic wounds. This will be accomplished in animal models of impaired wound healing using non-invasive optics to monitor wound healing and b) develop a hydrogel that achieves controlled release of NO to the tissue. The broader/commercial impacts of this research are significant: if successful, the product developed could reduce the estimated US healthcare costs of more than $10 billion annually associated with treating diabetic foot ulcers and related amputations. Furthermore, approximately 3.2 million Americans who are affected by leg ulcers would be provided with effective treatment. Recurrence rate of these ulcers is as high as 70% and the annual cost is estimated to be $3.5billion. Developing a commercial product that is cost effective and can be administered at any nursing care or wound care facility as a dressing will have a life altering impact on the quality of life for the patients and in reducing healthcare costs.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government